Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Jennifer H. Foster et al.|Neuro-Oncology|2022Cited by 136
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61
GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcomaJacqueline Morales, Amit J. Sabnis|JCI Insight|2022Cited by 7